Alzinova Q4: Bolstered by clinical progress - Redeye

Redeye provides a research update following the Q4 report published by Alzinova earlier today. The company reported a slightly higher OPEX and investment in intangibles than anticipated. Accordingly, the company increased its overall cash burn as it has intensified preparations ahead of the upcoming phase II trial. Bolstered by the recent positive phase Ib extension study results, the main focus ahead will be to achieve a licensing deal for ALZ-101.

Länk till analysen i sin helhet: https://www.redeye.se/research/1084220/alzinova-q4-bolstered-by-clinical-progress?utm_source=finwire&utm_medium=RSS